Drugs / Copaiba
Copaiba
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05308732 | May 2021 → Sep 2025 overdue | head and neck neoplasm, mucositis | Brazilian National Cancer Institute | Active not recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06708702 | Jan 2025 → Jan 2026 | mucositis | Brazilian National Cancer Institute | Withdrawn | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT04127279 | Jan → Sep 2018 | — | University of Parma | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | copaiba | “A phase I study with copaiba (CPB) in patients with oral cancer undergoing RT was previously developed by this group.” NCT06708702 ↗ |
| Known as | Copaifera Officinalis Resin | “The enriched cream is self-administered and contains a blend of 4 essential oils, namely Juniperus phoenicea gum extract, Copaifera officinalis resin, Aniba rosaeodora wood oil...” NCT04127279 ↗2“A 10% and 15% aqueous solution of copaiba (Copaifera Officinalis Resin) manufactured by Interativo Farmácia de Manipulação will be used” NCT05308732 ↗ “A 15% aqueous solution of copaíba (Copaifera Officinalis Resin) manufactured by Interativo Farmácia de Manipulação will be used” NCT06708702 ↗ |
| Known as | CPB | “A phase I study with copaiba (CPB) in patients with oral cancer undergoing RT was previously developed by this group.” NCT06708702 ↗ |
| Route | Other | “copaiba-based mouthwash” NCT05308732 ↗ |